Gemphire Therapeutics Inc (NASDAQ:GEMP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday.

According to Zacks, “Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company’s product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. “

Other analysts also recently issued research reports about the stock. Jefferies Group started coverage on shares of Gemphire Therapeutics in a report on Tuesday, August 30th. They issued a “buy” rating and a $15.00 price objective for the company. Canaccord Genuity started coverage on shares of Gemphire Therapeutics in a report on Tuesday, August 30th. They issued a “buy” rating and a $17.00 price objective for the company. Laidlaw started coverage on shares of Gemphire Therapeutics in a report on Tuesday, September 6th. They issued a “buy” rating and a $20.00 price objective for the company. RBC Capital Markets reiterated an “outperform” rating and issued a $25.00 price objective on shares of Gemphire Therapeutics in a report on Friday, September 16th. Finally, Royal Bank Of Canada started coverage on shares of Gemphire Therapeutics in a report on Tuesday, August 30th. They issued an “outperform” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $20.80.

Analyst Recommendations for Gemphire Therapeutics (NASDAQ:GEMP)

Shares of Gemphire Therapeutics (NASDAQ:GEMP) opened at 9.47 on Thursday. The stock’s market cap is $87.79 million. Gemphire Therapeutics has a one year low of $8.50 and a one year high of $13.98. The company has a 50 day moving average price of $10.07 and a 200-day moving average price of $10.47.

Gemphire Therapeutics (NASDAQ:GEMP) last released its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.45) by $0.11. Equities analysts predict that Gemphire Therapeutics will post ($2.11) earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Monashee Investment Management LLC purchased a new stake in shares of Gemphire Therapeutics during the third quarter worth about $144,000. Spark Investment Management LLC bought a new position in Gemphire Therapeutics during the third quarter worth $198,000. Adage Capital Partners GP L.L.C. bought a new position in Gemphire Therapeutics during the third quarter worth $3,976,000. Finally, Blue Clay Capital Management LLC bought a new position in Gemphire Therapeutics during the third quarter worth $131,000.

About Gemphire Therapeutics

Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of dyslipidemia. It is developing its product candidate Gemcabene (CI-1027), once-daily, oral therapy, for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.

5 Day Chart for NASDAQ:GEMP

Receive News & Stock Ratings for Gemphire Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc and related stocks with our FREE daily email newsletter.